Blog
22
Sep 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
22
Jul 2022
Fueling continuous innovation at BenevolentAI
BenevolentAI’s CTO, Daniel Neil, discusses the approaches we use to fuel continuous innovation in order to unlock new opportunities and future growth.
12
May 2022
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
03
Feb 2022
Please don’t use this sentence out of context
BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of context in information extraction.
